Representatives from the Christian Social Union (CSU), a center/conservative political party in Germany, focused regionally in the southern part of Germany, have recently forth a communication calling for the German government to fund ivermectin research in association with COVID-19. The CSU parliamentary group now campaigns for an ivermectin investigation as part of the government’s support of COVID-19 research. Putting forth an application to the health committee, this Bavarian political party requests that the German government support meaningful clinical studies to enable testing against the coronavirus. Led by Bernhard Seidenath, Chairman of the Committee on Health and Care for the Bavarian State Parliament, this group seeks to investigate whether ivermectin-based therapies could be procured for the wide spread regional treatment of COVID-19 patients.
Mr. Seidenath went on the record, “In the fight against Corona, we have to pull out all the stops to prevent serious courses and deaths. This includes tests, vaccinations, but also the development of new drugs against Covid-19. In particular, we must not neglect the experience of other countries here. This also includes experience with existing drugs such as ivermectin. It is our goal to test the effectiveness as quickly as possible so that it can be given to doctors who want to prescribe it for the treatment of a corona infection.”
€50 Euro Research Fund Proposed to Include Ivermectin
Parliamentary managing director of the CSU parliamentary group Tobias Reiss shared “Ivermectin is a drug with antiviral and anti-inflammatory properties, for the development of which the Nobel Prize was awarded and which has been used for decades without any noteworthy side effects. I therefore advocate provisionally and temporarily approving ivermectin and supporting it with studies, because in addition to vaccination we absolutely need a second barrier with therapeutic agents against the virus.
Our goal in Bavaria is to continuously expand the treatment options for Corona. With our Bavarian Therapy Strategy, we are therefore investing 50 million euros in promoting the development of new drugs and therapies. The selection process is about to be completed here. “
Robert Koch Institute Includes Ivermectin
The Robert Koch Institute is a German federal government agency and research institute responsible for disease control and prevention. Located in Berlin and Wernigerode, the agency falls under the German Federal Minister of Health and is named for its founding director, the founder of modern bacteriology and Nobel laureate Robert Koch.
According to the CSU press release, specialist groups associated with the Robert Koch Institute already identify ivermectin as a potentially effective agent targeting COIVD-19. But thus far, the use of this generic drug as a prophylaxis and therapy for COVID-19 can thus far only be done so for research.
Germany Media Fact Check
Interestingly, in Germany, the global media Deutsche Welle (DW) fact check for ivermectin lists two sources, one against and one pro. They note that the World Health Organization (WHO) only advises use of the drug for COVID-19 in the context of research while for the pro, or favorable, use they refer to the U.S.-based Frontline COVID-19 Critical Care Alliance or FLCCC.
TrialSite has inquiries to learn more about the CSU ivermectin research stance and the timeline for any clinical trials, as well as the number of clinical trials the 50 million Euros are planned to support.